Is Zoledronate Toxic to Human Periodontal Fibroblasts?

被引:54
作者
Agis, H. [1 ]
Blei, J. [1 ]
Watzek, G. [1 ]
Gruber, R. [1 ]
机构
[1] Med Univ Vienna, Dept Oral Surg, A-1090 Vienna, Austria
关键词
zoledronate; osteonecrosis; gingival fibroblasts; periodontal ligament; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS; ACID; OSTEOCLASTS; JAW; DIFFERENTIATION; PROLIFERATION; MECHANISM; THERAPY; BREAST;
D O I
10.1177/0022034509354298
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Exposed necrotic alveolar bone is a hallmark of bisphosphonate-related osteonecrosis of the jaw. However, it is unknown whether zoledronate causes soft-tissue damage via adverse actions toward periodontal fibroblasts. We therefore examined whether zoledronate causes a cytotoxic response in fibroblasts isolated from the gingiva and the periodontal ligament. We report that micromolar concentrations of zoledronate and serum-free conditions decreased cell activity, as measured by assays for formazan formation, proliferation, and protein synthesis. Under these conditions, periodontal fibroblasts underwent apoptosis and necrosis, as indicated by cleavage of PARP and membrane disruption, respectively. However, these adverse effects of zoledronate were mitigated by the presence of serum. Moreover, zoledronate bound to calcium phosphate failed to reduce cell activity. Analysis of these data suggests that the cytotoxic responses of periodontal fibroblasts require high concentrations of zoledronate and depend on the in vitro experimental conditions. Whether these findings translate into soft-tissue damage will require further investigation.
引用
收藏
页码:40 / 45
页数:6
相关论文
共 29 条
[1]  
ALLEN MR, 2009, J ORAL MAXILLOFAC S, V67, pS61
[2]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[3]  
Chang JT, 2003, NEW ENGL J MED, V349, P1676
[4]   Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases [J].
Chen, TL ;
Berenson, J ;
Vescio, R ;
Swift, R ;
Gilchick, A ;
Goodin, S ;
LoRusso, P ;
Ma, PM ;
Ravera, C ;
Deckert, F ;
Schran, H ;
Seaman, J ;
Skerjanec, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1228-1236
[5]  
Corey E, 2003, CLIN CANCER RES, V9, P295
[6]   Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells [J].
Coxon, Fraser P. ;
Thompson, Keith ;
Roelofs, Anke J. ;
Ebetino, F. Hal ;
Rogers, Michael J. .
BONE, 2008, 42 (05) :848-860
[7]   Pharmacokinetics/pharmacodynamics of bisphosphonates - Use for optimisation of intermittent therapy for osteoporosis [J].
Cremers, SCLM ;
Pillai, GC ;
Papapoulos, SE .
CLINICAL PHARMACOKINETICS, 2005, 44 (06) :551-570
[8]   Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells [J].
Dumon, JC ;
Journé, F ;
Kheddoumi, N ;
Lagneaux, L ;
Body, JJ .
EUROPEAN UROLOGY, 2004, 45 (04) :521-528
[9]   Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease [J].
Dunstan, Colin R. ;
Felsenberg, Dieter ;
Seibel, Markus J. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (01) :42-55
[10]  
Ibrahim A, 2003, CLIN CANCER RES, V9, P2394